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 Long-Acting Bronchodilators and Arterial Stiff ness 
in Patients With COPD 
 A Comparison of Fluticasone Furoate/Vilanterol With Tiotropium 
 Jean-Louis  Pepin ,  MD ,  PhD ;  John R.  Cockcroft ,  MD ;  Dawn  Midwinter ,  MSc ;  Sanjay  Sharma ,  BSc ;  David B.  Rubin ,  MD ; 
and  Stefan  Andreas ,  MD 
 BACKGROUND:  Increased arterial stiff ness as measured by aortic pulse wave velocity (aPWV) 
predicts cardiovascular events and mortality and is elevated in patients with COPD. Prior inves-
tigation suggests that a long-acting  b -agonist (LABA)/inhaled corticosteroid (ICS) lowers 
aPWV in patients with baseline aPWV   11 m/s. Th is study compared the eff ect of the ICS/
LABA fluticasone furoate/vilanterol (FF/VI), 100/25  m g , delivered via the ELLIPTA dry 
powder inhaler, with tiotropium bromide (TIO), 18  m g, on aPWV. 
 METHODS:  Th is multicenter, randomized, blinded, double-dummy, parallel-group, 12-week 
study compared FF/VI and TIO, both administered once daily. Th e primary end point was 
aPWV change from baseline at 12 weeks. Safety end points included adverse events (AEs), 
vital signs, and clinical laboratory tests. 
 RESULTS:  Two hundred fi ft y-seven patients with COPD and aPWV   11 m/s were random-
ized; 87% had prior cardiovascular events and/or risk. Th e mean diff erence in aPWV between 
FF/VI and TIO at week 12 was not signifi cant ( P  5 .484). Because the study did not contain a 
placebo arm, a post hoc analysis was performed to show that both treatments lowered aPWV 
by an approximate diff erence of 1 m/s compared with baseline. Th e proportion of patients 
reporting AEs was similar with FF/VI (24%) and TIO (18%). Th ere were no changes in clinical 
concern for vital signs or clinical laboratory tests. 
 CONCLUSIONS:  No diff erences on aPWV were observed between FF/VI and TIO. However, 
further studies with a placebo arm are required to establish defi nitively whether long-acting 
bronchodilators lower aPWV. Both treatments demonstrated an acceptable tolerability profi le. 
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 Patients with COPD are at increased risk of death and 
disability from extrapulmonary complications. 1-3 In 
patients with COPD, cardiovascular diseases (CVDs) 
are the most common comorbidities 3 and one of the 
leading causes of hospitalization and death 4 ; COPD and 
CVDs complicate the prognosis of each other. 5 In patients 
with cardiovascular risk, identifying cardiovascular 
changes before the occurrence of major clinical events is 
critical. For this purpose, several markers of subclinical 
CVD have been validated. 
 Among the markers of cardiovascular risk, arterial stiff -
ness has a predictive value for cardiovascular events 
beyond traditional clinical cardiovascular risk factors 6 
and is suited for use in clinical practice. In COPD, arte-
rial stiff ness is independently associated with severity of 
emphysema 7 and airfl ow obstruction 8 and is elevated 
compared with healthy patients matched for age, BMI, 
and smoking history. Infl ammation, oxidative stress, 
and high sympathetic tone, linked to the severity of air-
way obstruction, are suspected mechanisms by which 
COPD leads to the development of increased arterial 
stiff ness and cardiovascular events. 9,10 
 Early results from interventions that may reduce arterial 
stiffness in patients with COPD have been reviewed 
recently 11 and a post hoc analysis of a randomized clin-
ical trial with salmeterol/fl uticasone propionate 11,12 
suggested that a long-acting  b -agonist (LABA)/inhaled 
corticosteroid (ICS) lowers aortic pulse wave velocity 
(aPWV) in patients with baseline aPWV   11 m/s. 
Diff erent classes of inhaled bronchodilators may impact 
cardiovascular events in patients with COPD, 13,14 and 
their safety as related to cardiovascular mortality is a 
topic of some discussion. 15 Assessing the impact of 
diff erent inhaled bronchodilators on arterial stiff ness 
may help increase understanding of cardiovascular 
benefi t/risk. We hypothesized that although diff erent 
classes of bronchodilators may induce decreases in 
arterial stiffness in patients with elevated baseline 
values, this decrease would be larger in subjects ran-
domized to fluticasone furoate/vilanterol (FF/VI). 
Therefore, we compared the effects of a LABA/ICS, 
FF/VI delivered via the ELLIPTA dry powder inhaler, 
and tiotropium bromide (TIO) on arterial stiffness 
over 12 weeks. 
 Materials and Methods 
 Study Design 
 Th e primary objective was to evaluate the eff ect of treatment with once-
daily FF/VI, 100/25  m g, compared with once-daily TIO, 18  m g, on 
arterial stiff ness measured as aPWV in patients with COPD and aPWV 
  11.0 m/s. Th is was a phase 3b comparator, blinded, double-dummy, 
randomized, parallel-group, multicenter study conducted at 46 centers 
in seven countries. Further details of the blinding procedure are pro-
vided in  e-Appendix 1 . 
 At screening, male or nonpregnant female patients aged   40 years 
with a history of COPD, a current or prior history of   10 pack-years 
of cigarette smoking, a post-albuterol/salbutamol FEV 1   70% of 
predicted normal, a FEV 1 /FVC ratio   0.70, and a measured aPWV 
  11.0 m/s were eligible. Exclusion criteria and details of concomitant 
medications are presented in  e-Appendix 2 . 
 Aft er a 2-week, single-blind, placebo run-in period, during which COPD 
stability and protocol compliance were assessed, eligible patients were ran-
domized (1:1) to treatment with FF/VI, 100/25  m g (via ELLIPTA device; 
GlaxoSmithKline), or TIO, 18  m g (via HandiHaler device; Boehringer 
Ingelheim GmbH), for 12 weeks. Salbutamol/albuterol was provided to 
use as needed throughout the run-in and treatment periods. A follow-up 
phone call was made approximately 7 days aft er the fi nal clinic visit. 
 At baseline, hemodynamic parameters, including aPWV, peripheral 
and central pulse pressure, and augmentation index (AIx), were recorded. 
Carotid-femoral aPWV was measured using tonometers positioned trans-
cutaneously at the base of the common carotid artery and over the femo-
ral artery by using the SphygmoCor CPV system (AtCor Medical Inc). 
Peripheral pulse pressure, defi ned as the diff erence between peripheral 
systolic BP and diastolic BP, was measured using a sphygmomanometer 
on the upper arm. Central (aortic) pulse pressure (measured using the 
SphygmoCor CPV system) is diff erent from the pulse pressure in dis-
tributing arteries because of reflective waves from vessel branching 
and from decreased arterial compliance, which leads to characteristic 
changes in the systolic, diastolic, and mean pressures. AIx was derived 
from measures of the pulse waves at the carotid and radial arteries 
and represents the time of pressure wave refl ection in relation to left -
ventricular systolic pressure. It is defi ned as the diff erence between the 
second and fi rst systolic peaks and was measured using the SphygmoCor 
CPV system. 
 Eﬃ  cacy Assessments 
 Carotid-femoral aPWV was measured at screening and on days 28, 
56, and 84. Other effi  cacy end points included change from baseline 
in trough FEV 1 and trough inspiratory capacity (prebronchodilator 
and predose) at the end of the treatment period (day 84). Additionally, 
central pulse pressure and AIx were evaluated by the SphygmoCor 
CPV system. All hemodynamic and vital sign measurements were per-
formed between 6:00  am and 10:00  am . Health outcome assessments 
were conducted on days 1 and 84 ( e-Appendix 3 ). 
 Safety Assessments 
 Safety end points were the proportion of patients reporting adverse 
events (AEs) and serious AEs (SAEs), including pneumonia. Vital 
signs (BP and pulse rate) were recorded at all study visits, including 
the prescreening visit if aPWV was also obtained. Clinical laboratory 
tests were performed at screening and at baseline (predose on day 1) 
and included liver function tests that were also performed on day 84. 
Abnormal oropharyngeal examinations were reported as AEs, and 
COPD exacerbation information was recorded at each clinic visit. 
 Statistical Methods 
 Data from a prior study 1 indicated that a reasonable estimate of SD of 
mean change from baseline in aPWV was 2.2 m/s. One hundred two 
patients per treatment group were estimated to provide 90% power to 
detect a treatment diff erence of 1 m/s in change from baseline in aPWV 
after 12 weeks at a significance level of .05, based on a two-sample, 
two-sided  t test. Two hundred forty-eight patients were planned, and 
no multiplicity adjustments were required. 
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 All effi  cacy and safety end points were summarized using the intent-to-
treat (ITT) population (patients randomized and treated with at least 
one dose of drug) unless otherwise stated. Th e primary analysis was 
performed using mixed-model repeated-measures (MMRMs) analysis 
of covariance with terms for visit, treatment, age, sex, smoking status at 
screening, geographical region, baseline aPWV, and interaction terms 
of baseline by visit and treatment by visit. Th e per-protocol population 
(patients in the ITT population not identifi ed as major protocol devia-
tions) was used to confi rm the primary end point analysis only. A sen-
sitivity analysis tested the interaction of covariates with treatment. 
If an interaction was observed, further investigation was conducted by 
fi tting a treatment-by-covariate-by-day interaction term to the model 
to evaluate whether there was an inconsistent treatment response on 
day 84. 
 A post hoc analysis of aPWV compared with baseline values was also 
conducted, using the last observation carried forward (LOCF) aPWV 
values for each patient; LOCF was considered an appropriate model 
for this exploratory analysis and was considered to be more power-
ful than an analysis of completers only (ie, patients with available 
results at week 12). Th is was analyzed separately for each treatment 
group using MMRM with the response variable of aPWV and the 
repeated explanatory variable of visit (baseline and LOCF visit only). 
 This study was conducted in accordance with the International 
Conference of Harmonisation : Guidance for Good Clinical Practice, 16 
the Declaration of Helsinki 2008, 17 and all applicable subject privacy 
requirements; approvals from Institutional Review Boards are pre-
sented in  e-Table 1 . Written informed consent was obtained from each 
patient prior to the performance of any study-specifi c procedures. 
  
 Figure 1 – Subject disposition for this study. See Results section for further 
detail. FF/VI  5 fl uticasone furoate/vilanterol; TIO  5 tiotropium bromide. 
 Results 
 Patient Disposition 
 Th e most common reason for failing screening was 
aPWV  , 11 m/s. Two hundred sixty patients were ran-
domized; three patients were determined not to meet 
the entry criteria prior to dispensing of the study drug. 
Accordingly, 257 patients were included in the ITT pop-
ulation ( Fig 1 ). Th e most common reason for withdrawal 
was AEs. Use of concomitant medication was stable 
throughout the course of the study. 
 Demographics and baseline characteristics were compa-
rable between the two treatment groups ( Tables 1, 2 , 
 e-Table 2 ). In this population with moderate to severe 
airfl ow obstruction, the mean aPWV at screening was 
12.91 m/s, and 87% had cardiovascular history/risk. All 
patients were white and mostly men, who tended to be 
overweight and mildly hypertensive. 
 Eﬃ  cacy 
 During the treatment period, mean changes from base-
line in aPWV were similar between treatment groups 
( Fig 2 ). At day 84, the adjusted mean change from base-
line was  2 0.859 m/s with FF/VI and  2 1.118 m/s with 
TIO, with an FF/VI vs TIO treatment difference of 
0.259 m/s, which was not statistically signifi cant. Results 
were similar for the per-protocol population (data not 
shown). 
 The interaction of treatment with smoking status at 
screening and baseline systolic BP were signifi cant at the 
10% level ( P  5 .029 and  P  5 .046, respectively); interac-
tions with sex, center grouping, and age were nonsignif-
icant. Th ere was no diff erential treatment response on 
day 84 by baseline systolic BP, and no evidence of a con-
sistent response for smoking status at screening. Th e 
numerical treatment diff erence was in favor of TIO in 
current smokers and favored FF/VI in former smokers. 
Th is numerical diff erence was also observed at day 56, 
but not day 28. Th ere were no statistically signifi cant dif-
ferences in the change of hemodynamic variables between 
study arms or in the changes over time ( e-Table 3 ). 
 Adjusted mean changes from baseline in trough FEV 1 
ranged from 0.093 to 0.117 L with FF/VI and from 
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 TABLE 1 ]  Baseline Demographics and Pulmonary Characteristics (ITT Population) 
Demographics and Pulmonary Characteristics FF/VI, 100/25  m g  (n  5 127) TIO, 18  m g (n  5 130) Total (N  5 257)
Demography
 Male, No. (%) 108 (85) 112 (86) 220 (86)
 Female, No. (%) 19 (15) 18 (14) 37 (14)
 Age, y 66.7 (7.20) 67.7 (7.34) 67.3 (7.28)
 Race, No. (%)
  Hispanic or Latino 24 (19) 28 (22) 52 (20)
  Not Hispanic or Latino 101 (80) 101 (78) 202 (79)
  Unknown 2 (2) 1 ( , 1) 3 (1)
 BMI, kg/m 2 27.07 (4.104) 27.17 (4.472) 27.12 (4.286)
 Height, cm 170.6 (7.06) 170.4 (6.75) 170.5 (6.90)
 Weight, kg 78.91 (13.355) 78.94 (13.997) 78.92 13.657)
Summary of smoking history
 Years smoked 39.8 (11.54) 39.8 (12.06) 39.8 (11.78)
 Cigarettes/d 21.8 (8.27) 22.4 (10.14) 22.1 (9.25)
 Smoking pack-y 42.6 (19.82) 44.6 (24.97) 43.6 (22.55)
 Current smoker, No. (%) 59 (46) 58 (45) …
Pulmonary function
 Prebronchodilator FEV 1 , a L 1.251 (0.4664) 1.290 (0.4463) 1.271 (0.4559)
 Postbronchodilator FEV 1 , a L 1.348 (0.4756) 1.381 (0.4469) 1.365 (0.4607)
 Prebronchodilator FVC, a L 2.563 (0.7677) 2.509 (0.7552) 2.536 (0.7604)
 Postbronchodilator FVC, a L 2.681 (0.7711) 2.682 (0.7708) 2.681 (0.7694)
 % Predicted prebronchodilator FEV 1 , a % 42.3 (13.86) 44.4 (13.96) 43.4 (13.93)
 % Predicted postbronchodilator FEV 1 , a % 45.6 (14.49) 47.4 (13.80) 46.5 (14.15)
 Postbronchodilator FEV 1 /FVC, a % 50.7 (11.51) 51.9 (10.75) 51.3 (11.13)
 % Reversibility FEV 1 , a % 8.5 (11.12) 8.5 (13.86) 8.5 (12.56)
 FEV 1 reversibility, a mL 97.0 (118.15) 91.1 (132.15) 94.0 (125.22)
 Baseline FEV 1 , b L 1.255 (0.4910) 1.293 (0.4719) 1.274 (0.4809)
 Baseline inspiratory capacity, b L 2.073 (0.6135) 2.172 (0.6831) 2.123 (0.6499)
 Baseline FVC, b L 2.526 (0.7524) 2.583 (0.7395) 2.555 (0.7450)
Summary of pretreatment concomitant 
  medication use, c No. (%)
 ACE inhibitor 64 (50) 73 (56) 137 (53)
 Anticoagulant 37 (29) 42 (32) 79 (31)
 Calcium channel blocker 31 (24) 37 (28) 68 (26)
 Statin 25 (20) 32 (25) 57 (22)
 Antidiabetic 11 (9) 20 (15) 31 (12)
  b -Blocker 14 (11) 15 (12) 29 (11)
Data are presented as mean (SD) unless indicated otherwise. ACE  5 angiotensin-converting enzyme inhibitor; FF/VI  5 ﬂ uticasone furoate/vilanterol; 
ITT  5 intent-to-treat; TIO  5 tiotropium bromide. 
 a Assessed at screening visit, prior to 2-wk ﬂ uticasone propionate/salmeterol run-in period. 
 b Assessed at baseline visit, following 2-wk ﬂ uticasone propionate/salmeterol run-in period and prior to ﬁ rst dose of study drug.
 c Medication classes were selected because they reﬂ ect cardiovascular risk and/or disease and, with the exception of anticoagulants, have been shown 
to modify arterial stiﬀ ness. 
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0.032 to 0.084 L with TIO over the course of treatment, 
with the greatest improvements in both treatment groups 
at day 84 ( Table 3 ). Differences in adjusted mean 
changes from baseline in trough FEV 1 and trough 
inspiratory capacity between FF/VI and TIO groups at 
day 84 were small (0.037 L and 0.070 L, respectively). 
FVC data are presented in  e-Table 4 . Th e assessment of 
health outcome results demonstrated no statistically 
signifi cant diff erences between FF/VI and TIO group 
( e-Table 5 ). 
 Safety 
 Th e proportion of patients who reported on-treatment 
AEs ( e-Table 6 ) was similar with FF/VI (n  5 31 [24%]; 
treatment-related, n  5 4 [3%]) and TIO (n  5 34 [26%]; 
treatment-related, n  5 7, [5%]). Fifteen patients (5%) 
withdrew because of AEs (run-in, n  5 1; FF/VI, n  5 8; 
TIO, n  5 6). The most frequently reported AEs (  3% 
in either treatment group) were COPD worsening/
exacerbation, nasopharyngitis, and headache ( Table 4 ); 
supraventricular extrasystoles (FF/VI, n  5 1; TIO, 
n  5 3) and headache (FF/VI, n  5 1; TIO, n  5 1) were 
the only treatment-related AEs reported by more than 
one patient. On-treatment SAEs were reported by seven 
patients (6%) with FF/VI and by eight patients (6%) 
with TIO; one was considered to be treatment-related 
(TIO: COPD exacerbation) and two were fatal but were 
not considered to be treatment-related (both TIO: one 
 TABLE 2 ]  Baseline Hemodynamic Indexes, Cardiovascular History, and Risk History (ITT Population) 
Hemodynamic Indexes FF/VI, 100/25  m g (n  5 127) TIO, 18  m g (n  5 130) Total (N  5 257)
aPWV, a m/s 12.84 (1.918) 12.97 (1.891) 12.91 (1.902)
Augmentation index, a % 27.0 (11.24) 25.7 (10.46) 26.3 (10.86)
Central diastolic BP, a mm Hg 83.9 (11.17) 83.3 (9.63) 83.6 (10.41)
Central systolic BP, a mm Hg 129.1 (17.84) 128.3 (16.43) 128.7 (17.12)
Central pulse pressure, a mm Hg 45.2 (14.81) 45.0 (12.43) 45.1 (13.64)
Peripheral diastolic BP, a mm Hg 82.8 (10.96) 82.3 (9.55) 82.5 (10.25)
Peripheral pulse pressure, a mm Hg 58.0 (15.94) 57.6 (13.44) 57.8 (14.70)
Peripheral systolic BP, a mm Hg 140.8 (18.22) 139.9 (16.62) 140.3 (17.40)
Cardiovascular disease history 
 and risk factors, No. (%)
 Any cardiovascular risk factor 107 (84) 116 (89) 223 (87)
 Hypertension 96 (76) 98 (75) 194 (75)
 Hypercholesterolemia 52 (41) 53 (41) 105 (41)
 Coronary artery disease 42 (33) 40 (31) 82 (32)
 Congestive heart failure 23 (18) 19 (15) 42 (16)
 Diabetes mellitus 11 (9) 19 (15) 30 (12)
 Myocardial infarction 9 (7) 15 (12) 24 (9)
 Arrhythmia 9 (7) 7 (5) 16 (6)
 Cerebrovascular accident 1 ( , 1) 5 (4) 6 (2)
COPD history, No. (%)
 Chronic bronchitis 111 (87) 104 (80) 215 (84)
 Emphysema 58 (46) 67 (52) 125 (49)
 Data are presented as mean (SD) unless indicated otherwise. aPWV  5 aortic pulse wave velocity. See  Table 1 legend for expansion of other abbreviations.  
 a Assessed at screening visit, prior to 2-wk ﬂ uticasone propionate/salmeterol run-in period. 
 Figure 2 – LS mean change from baseline in aortic pulse wave velocity 
(aPWV) (m/s) (intent-to-treat population). Analysis was performed 
using a repeated-measures model with covariates of treatment, visit, age, 
sex, smoking status at screening, geographical region, baseline aPWV, 
and interaction terms of baseline by visit and treatment by visit. 
LS  5 least squares. See  Figure 1 legend for expansion of other 
abbreviations. 
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pulmonary embolism after abcessectomy and one car 
accident). AEs of special interest included pneumonia 
reported as an SAE (FF/VI: on-treatment, n  5 2; post-
treatment, n  5 1), cardiovascular events (FF/VI, n  5 3; 
TIO, n  5 4) and local steroid effects (FF/VI, n  5 3); 
additionally, hand fracture (n  5 1), bronchitis (n  5 1), 
and cataract (n  5 1) were reported by patients in the 
FF/VI group only. Th ere were no statistically signifi cant 
changes in vital signs. Few patients in either treatment 
group (n   4 [3%]) had changes from baseline to any 
postbaseline visit that were outside the normal range 
for any liver chemistry parameter; none of the changes 
was of clinical concern. 
 Post Hoc Analysis 
 Because raw mean values of aPWV fell by approxi-
mately 1 m/s from baseline in both treatment groups 
( Fig 3 ), post hoc analyses that compared LOCF values 
with baseline values were conducted. Both treatments 
lowered aPWV compared with baseline to a level 
approximating a meaningful clinical diff erence of 
1 m/s (FF/VI:  2 0.9 m/s,  P  5 .0024; TIO:  2 1.1 m/s, 
 P  5 .0006). To determine whether patient characteristics 
related to aPWV responsiveness to bronchodilators, a 
responder analysis was conducted. 
 Th e following screening and/or baseline characteristics 
were explored for responders (  1 m/s reduction of 
aPWV from baseline) as compared with nonresponders 
( , 1 m/s reduction from baseline or missing): (1) lung 
function, (2) central and peripheral pressure measures, 
(3) aPWV, (4) cardiovascular risk/history, and (5) con-
comitant medications. No characteristics of responders 
were identifi ed except for a slightly better pulmonary 
function in the responders ( e-Table 7 ). 
 Th e change from baseline in aPWV was signifi cantly 
correlated to the change from baseline for both central 
mean arterial pressure (MAP) (Pearson correlation 
coeffi  cient: 0.26613,  P  5 .0002) and peripheral MAP 
(Pearson correlation coeffi  cient: 0.22751,  P  5 .0010) 
( e-Table 8 ); however, the change from baseline central 
and peripheral MAP contributed to only 7% and 5%, 
respectively, of aPWV variability. Th e results from the 
analysis of covariance, adjusting for post baseline MAP 
at each visit, do not impact the conclusions drawn from 
the primary MMRM analysis ( e-Table 9 ). 
 TABLE 3 ]  Pulmonary Function at End of Trial (Day 84) (ITT Population) 
Pulmonary Function FF/VI, 100/25  m g (n  5 127) TIO, 18  m g (n  5 130)
Trough FEV 1 at day 84
 No. a 117 122
 No. b 112 112
 LS mean, L 1.406 1.368
 LS mean change, L (SE for mean/mean change) 0.117 (0.0221) 0.080 (0.0219)
 FF/VI vs TIO
  Diﬀ erence 0.037
  95% CI  2 0.024, 0.099
   P value .232
Trough inspiratory capacity at day 84
 No. a 108 111
 No. b 104 100
 LS mean, L 2.227 2.158
 LS mean change, L (SE for mean/mean change) 0.089 0.019
 FF/VI vs TIO
  Diﬀ erence 0.070
  95% CI  2 0.045, 0.184
   P value .231
 Analysis performed using a repeated-measures model with covariates of treatment, age, sex, smoking status, geographical region, baseline aPWV, 
FEV 1 , or inspiratory capacity (as applicable), and interaction terms of baseline by visit and treatment by visit. LS  5 least squares. See  Table 1 
and 2 legends for expansion of other abbreviations.  
 a No. patients with analyzable data for one or more time points. 
 b No. patients with analyzable data at day 84. 
 journal.publications.chestnet.org  1527 
 TABLE 4 ]  Summary of Most Frequent On-Treatment Adverse Events (ITT Population) 
Adverse Events FF/VI, 100/25  m g (n  5 127) TIO 18,  m g (n  5 130)
Any adverse event 31 (24) 34 (26)
Top ﬁ ve most commonly reported on-treatment adverse events a 
 COPD (worsening or exacerbation) 5 (4) 7 (5)
 Nasopharyngitis 5 (4) 4 (3)
 Headache 3 (2) 5 (4)
 Arthralgia 3 (2) 2 (2)
 Dyspnea 3 (2) 1 ( , 1)
 Supraventricular extrasystoles 1 ( , 1) 3 (2)
 Back pain 1 ( , 1) 2 (2)
 Asthenia 0 2 (2)
Most frequent adverse events (  3% in either treatment group)
 COPD (worsening or exacerbation) 5 (4) 7 (5)
 Nasopharyngitis 5 (4) 4 (3)
 Headache 3 (2) 5 (4)
 Data are presented as No. (%). See  Table 1 legend for expansion of abbreviations. 
 a In each treatment group. 
 Figure 3 – Raw mean change from baseline in aortic pulse wave velocity 
(m/s) (intent-to-treat population). A post hoc analysis was performed 
using a mixed model repeated-measures for each treatment group sepa-
rately. Raw mean changes from baseline data are presented graphically; 
however, the analysis showed that the adjusted mean diff erence from the 
last observation carried forward visit to the baseline visit for FF/VI was 
 2 0.9 m/s ( P  5 .0024) and for TIO was  2 1.1 m/s ( P  5 .0006). See  Figure 
1 and  2 legends for expansion of abbreviations. 
 Discussion 
 No statistically signifi cant treatment diff erence between 
FF/VI and TIO was observed for the primary end point 
of aPWV. Our study included patients with an elevated 
arterial stiff ness (aPWV   11 m/s); thus, it was not sur-
prising that 87% of patients reported cardiovascular 
history/risk. Given the strong, independent association 
of arterial stiff ness with CVD, 7 and because CVDs are 
common and the most important comorbidities in 
COPD, 18,19 it is important that our post hoc analysis 
suggesting eff ects of inhaled COPD therapy on aPWV 
be confi rmed by further randomized controlled trials 
that include a placebo arm. 
 Arterial stiff ness is a sign of early cardiovascular damage 
and predisposes damage of other organs such as the heart, 
brain, and kidneys. 7,20,21 Noninvasive measurement of 
carotid-femoral pulse wave velocity is a surrogate for 
aPWV and is the “gold standard” for assessment of arte-
rial stiff ness. 7,20 In a previous meta-analysis, 21 aPWV was 
a strong predictor of future cardiovascular events and 
all-cause mortality. Th e elevation of aPWV in COPD 8,9 
relates to emphysema severity independent of smoking, 
age, sex, FEV 1 % predicted, and other cardiovascular risk 
factors. 7 In a large study, an independent correlation 
between lung function and arterial stiff ness was present, 22 
and in a multiethnic study of  . 3,500 patients, small- and 
large-artery elasticity were associated with FVC and FEV 1 
measured 5 years later. 23 Furthermore, the SphygmoCor 
system, as used in this study, has excellent reproducibility 24 
and has been used in a number of large studies, including 
the Anglo Cardiff  Collaborative Study (ACCT) 25 and the 
Chronic Renal Insuffi  ciency Cohort (CRIC). 26 
 Clinical trials suggest that bronchodilator therapy may 
reduce mortality and cardiovascular events, 4 and one 
of the mechanisms that may infl uence this is lowering 
arterial stiff ness. Treatment with fl uticasone propionate/
salmeterol, 250/50  m g bid, over 12 weeks decreased aPWV 
by 0.42 m/s, but this was not signifi cant compared with 
placebo. 12 However, in a post hoc analysis, the eff ect 
was statistically significant in patients with high base-
line aPWV; accordingly, the current study targeted this 
population. 
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 Tobacco consumption, 27,28 BP, and antihypertensive 
medications 20,29 are the main determinants of aPWV. In 
our study, BP did not change and correction for central 
artery pressure did not impact the fi ndings. Furthermore, 
smoking prevalence and medications were stable during 
the study. Th us, our results are not explained by changes 
in smoking prevalence, BP, or cardiovascular medications. 
A large body of epidemiologic evidence demonstrates 
that an increase of aPWV of approximately 1 m/s will 
occur in a decade of life, 30 increasing cardiovascular 
mortality by approximately 15%. 21 Despite this, we cannot 
be certain that a reduction in aPWV of 1 m/s would be 
clinically meaningful because there are no available out-
come studies specifi c to COPD. However, preliminary 
data from the Assessment of Risk in Chronic Airways 
Disease Evaluation (ARCADE) study has shown an 
increase in aPWV of 0.7 m/s over 2 years in patients 
with COPD relative to matched control subjects who 
showed no increase over the same period. 31 Such an 
increase would be expected to increase the frequency of 
cardiovascular events, suggesting that, if sustained, a 
reduction of 1 m/s would be clinically relevant. Data 
from the ongoing Study to Understand Mortality and 
Morbidity in COPD (SUMMIT), assessing mortality 
and morbidity in COPD, 32 in which aPWV is being 
measured with the SphygmoCor system, in a subset of 
subjects, may provide evidence of clinical usefulness. 
 Although, mechanistically, stroke volume may infl uence 
aPWV, heart rate and, most importantly, path-length 
measurement, are the major sources of error. 33 Th ere 
were no signifi cant diff erences in heart rate, and we 
used the subtraction method, which has been validated 
invasively, to measure path length. 34 Although we did 
not measure cardiac output, a change in cardiac output 
substantial enough to produce a decrease in aPWV of 
1 m/s is highly unlikely. 
 Another driver of arterial stiffness in COPD that is 
thought to increase smooth muscle tone is neurohumoral 
activation, 35,36 which enhances the inflammatory 
response and is probably linked to the systemic disease 
related to COPD. 4,37,38 We speculate that bronchodilators 
could lower arterial stiff ness by improving the infl ation 
refl ex 37-39 or hypoxemia 37 that can drive neurohumoral 
activation in patients with COPD; however, we did not 
measure infl ammatory biomarkers in this study. Th e 
safety profi les of FF/VI and TIO were similar, and there 
was no indication that FF/VI was related to a higher 
frequency of AEs, although this was only a 12-week 
study. Cardiovascular events have been associated with 
the administration of LABAs, such as VI, and with long-
acting muscarinic antagonists, such as TIO; in this study, 
the frequency of cardiovascular events was low (  3% in 
either treatment group), which is noteworthy because of 
the high frequency of CVD comorbidities reported by 
patients.  
 As expected for ICS-containing therapies, local steroid 
effects were reported only by patients in the FF/VI 
group. Only one SAE (COPD exacerbation) was consid-
ered to be related to TIO treatment, and no fatalities 
were considered to be treatment related. The three 
cases of pneumonia reported as SAEs with FF/VI (two 
on-treatment; one posttreatment) were not considered 
to be treatment related; however, previous observations 
have shown that ICS use can increase the risk of 
pneumonia in patients with COPD. 40,41 Th ere were no 
changes in clinical concern related to vital signs or 
clinical laboratory measurements in either treatment 
group. 
 Strength and Limitations 
 To the best of our knowledge, this is the largest ran-
domized clinical controlled trial to date in patients with 
COPD and elevated aPWV specifi cally comparing the 
eff ects on arterial stiff ness of two inhaled therapies that 
have diff erent modes of action for altering airway tone. 
A potential limitation is that our study cannot prove the 
causality of associations that we describe. Furthermore, 
because we included patients with aPWV above a cer-
tain threshold, regression to the mean may explain the 
observed decrease in aPWV; the inclusion of a placebo 
arm would have allowed us to reduce or eliminate this 
eff ect. Further studies should prospectively investigate 
the impact of bronchodilators on aPWV. 
 Conclusions 
 No statistically signifi cant diff erences in aPWV were 
observed between FF/VI and TIO. However, the results 
from the post hoc analysis suggest that long-acting 
bronchodilators may lower aPWV in patients with 
COPD and baseline elevated values. If replicated in a 
placebo-controlled study, our results may be of impor-
tance when considering ways to improve the increased 
cardiovascular morbidity and mortality of patients with 
COPD. Overall, both FF/VI and TIO were well tolerated 
in this 12-week study. 
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